You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
Imfinzi approved in EU for perioperative treatment of early gastric and gastroesophageal cancers
Login
Username:

Password:


Related Headlines

WuXi Biologics wins at 2026 Asia-Pacific Biopharma Excellence Awards for leadership in bioprocessing, manufacturing excellence, and digital innovation

Precision for Medicine opens new Japan office

Gesynta Pharma doses first patient in vipoglanstat Phase 2 clinical proof-of-concept trial

Avene partners with BotDesign to advance clinical studies in dermo-cosmetics

AnaCardio secures US patent for AC01, extending protection until 2042

Dexcom highlights new diabetes outcomes and product roadmap at ATTD 2026

Curatis and Neupharma partner to develop corticorelin for peritumoral brain edema in Japan

Samsung Biologics collaborates with Lilly for new Gateway Labs site in Korea

Citius Oncology reports positive topline results from Phase 1 clinical trial of LYMPHIR combination

CMIC agrees agentic AI partnership with Bluenote

GenomOncology partners with WeTrials to support CNS cancer clinical trials

Target ALS awards two-year research grant to AcuraStem for advancing therapeutics targeting SYF2

Ascletis reports Phase II weight‑loss results for ASC30 depot formulation

NS Pharma and NCNP report 4.5-year brogidirsen data for DMD treatment

Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026